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Abstract
Purpose: To compare efficacy and safety results of an ab interno gel implant in patients with pseudoexfoliation
glaucoma (PXG) and primary open angle glaucoma (POAG).
Methods: Retrospective analysis of the medical records of 110 consecutive eyes with open angle glaucoma who
had received a XEN45 gel implant between March 2014 and June 2015. Intraocular pressure course, number of
glaucoma medications, the need for additional intervention (including needling) and complications were evaluated
until 12 months postoperatively.
Results: Data of 67 eyes with POAG and 43 eyes with PXG were analyzed. At 12 months postoperatively, the mean
IOP had significantly decreased by 54.0% from preoperatively 31.85 ± 8.5 mmHg to 13.99 ± 2.6 mmHg in the POAG
group, (p = 0.000; Wilcoxon test), and by 55.2% from 31.63 ± 9.0 mmHg to 13.28 ± 3.1 mmHg in the PXG group
(p = 0.000; Wilcoxon test). The mean number of anti-glaucoma medications had significantly decreased from 3.
25 ± 0.8 at baseline to 0.3 ± 0.7 medications at 12 months postoperatively in POAG eyes (p = 0.000; Wilcoxon
test), and from 3.05 ± 1.0 to 0.3 ± 0.6 medications in PXG eyes (p = 0.000; Wilcoxon test). Hypotony (IOP ≤ 6
mmHg) was observed in 2 POAG eyes (3.0%) and in 5 PXG eyes (11.7%) at 1 month but normalized in all
eyes at 12 months postoperatively. Severe complications were not observed. No statistically significant
differences were found between PXG eyes and POAG eyes.
Conclusion: Our data indicate that the XEN45 gel implant provides significant and comparable reduction in IOP and
anti-glaucoma medication during the one-year follow-up period in POAG as well as PXG eyes. This suggests that it may
be a noteworthy alternative to traditional filtering procedures in patients with POAG and PXG respectively.
Keywords: Pseudoexfoliation glaucoma, Primary open angle glaucoma, Microinvasive glaucoma surgery,
XEN45 gel implant
Introduction
Glaucoma, a progressive optic neuropathy leading to
retinal ganglion cell loss and visual field defects, is still
one of the leading causes of irreversible blindness [1,
2]. An elevated intraocular pressure (IOP) is a major
risk factor for glaucoma development and progression -
and lowering IOP is still the only treatment option for
glaucoma [3]. Surgical options may be taken into
account in patients whose IOP is not sufficiently con-
trollable with two medications and have to be consid-
ered if maximally tolerated medical therapy fails [4].
Trabeculectomy is the gold standard filtering surgery
with good efficacy; however, it requires a strict postop-
erative follow-up and has several intra- and postopera-
tive complications [5–7]. In recent years, various
micro-invasive glaucoma surgery (MIGS) techniques
have been created to provide IOP reduction in a less
invasive and safer way [8]. Of these, the XEN45 gel
implant (XEN45) (Allergan, California USA) is the only
commercially available MIGS device that uses the same
outflow pathway as the surgical gold standard
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trabeculectomy by creating a permanent shunt from
the anterior chamber to the subconjunctival space with-
out the need of opening the conjunctiva [8–10]. It is a
6 mm long hydrophilic gelatin tube with an internal
diameter of 45 μm that had been designed to maximize
long-term outflow while at the same time providing
sufficient flow resistance to prevent hypotony [10–13].
Clinical studies have shown that the XEN45 gel implant
provides a significant and sustained reduction in IOP
and glaucoma medication with a low rate of complica-
tions [14–19]. However, most data were collected in pa-
tients with primary open angle glaucoma (POAG). In
this context, it should be noted that in Europe, the indica-
tion of the XEN45 gel implant is limited for patients with
POAG, whereas in the USA, the indication also includes
the management of refractory glaucoma, including cases
where previous surgical treatment has failed, cases of pri-
mary open angle glaucoma, and pseudoexfoliative or pig-
mentary glaucoma with open angles that are unresponsive
to maximum tolerated medical therapy [20, 21].
To our knowledge, this is the first study to evaluate
and compare the efficacy of the XEN45 gel implant in
POAG and pseudoexfoliation glaucoma (PXG) patients
with inadequately controlled IOP despite maximized
medical therapy or prior glaucoma surgery.
Methods
This is a retrospective analysis of consecutive patients
with PXG and POAG who received a XEN45 gel
implant between March 2014 and June 2015. The ana-
lysis included only the medical records of patients for
whom data on all follow-up visits up to 12 months after
surgery were available.
Patients and assessments
The medical records of 67 eyes with POAG and 43 eyes
with PXG were included in the analysis. Patients with
an inadequately controlled IOP and optic disc damage
despite prior surgical intervention or maximum medi-
cation as well as an area of healthy, free and mobile
conjunctiva in the target quadrant had received a
XEN45 implant. Exclusion criteria were the same as for
trabeculectomy: pregnancy, age < 18 years, condition
after pars plana vitrectomy, flat anterior chamber and
narrow chamber angle. Preoperatively, a complete oph-
thalmic examination including gonioscopy had been
performed. Postoperative evaluations were conducted
at day 1, week 1, and months 1, 3, 6, and 12. At each
visit, slit-lamp examination, gonioscopy, IOP assess-
ment by Goldmann applanation tonometry (at each as-
sessment, three measurements were performed, the
mean value was recorded), as well as evaluation of the
posterior pole were carried out. Moreover, the number
of medications and adverse events were documented.
Surgical technique
All implantations were performed by one single surgeon
(FHH) following a standardized implantation technique
which has been described in detail in a recent publica-
tion [14]. The vast majority of XEN implants were per-
formed as a stand-alone procedure. In brief, the XEN45
was implanted under peribulbar anesthesia using an ab
interno approach. At first, a volume of 0.1 ml of MMC
solution (0.01% mitomycin C, a total dose of 10 μg) was
injected subconjunctivally in the nasal superior quadrant
to prevent further scarring of the conjunctiva. After the
anterior chamber was filled with a medium grade visco-
elastic device, the preloaded injector needle was then
inserted through a 1.2 mm corneal paracentesis incision
opposite the site of desired implantation. The needle
was then directed across the anterior chamber and the
injector tip was used to penetrate through the chamber
angle above trabecular meshwork and the sclera at least
3 mm in length in order to place the implant properly.
After careful removal of viscoelastic and hydration of
paracenteses the eye was covered with a patch.
Postoperatively, topical antibiotics were given 4 times
daily for 10 days in combination with steroids 6 times
daily and tapered out over 6 weeks. Anti-glaucoma
medication was given until surgery and was completely
stopped after the implantation of the gel implant; there
was no wash-out phase. At every visit, IOP was
assessed and if IOP was elevated, additional anti-glau-
coma medication or secondary intervention were given
at the discretion of the surgeon. In case of conjunctival
scarring and bleb failure due to Tenon’s cyst formation,
a needling procedure was performed under microscopic
view in the operating room. The needling technique has
recently been described in detail [14]. The administration
of additional drugs during the needling was considered on
a case-by-case basis. Only in cases of pronounced fibrosis
(approx. 10% of cases) 10 μg mitomycin C was injected
during needling, while in eyes with cystic fibroses no add-
itional drugs were used.
Statistical analysis
Efficacy outcomes included IOP and the number of
anti-glaucoma medications, and their changes as com-
pared to baseline. Additional efficacy outcomes were tar-
get IOP of ≤18mmHg, ≤ 15mmHg and ≤ 13mmHg at 12
months. Safety outcomes included hypotony rate (IOP ≤ 6
mmHg), rate of needling, as well as complications. Data
were presented as mean and standard deviation, unless
otherwise indicated. Baseline IOP was the IOP measured
at the preoperative visit on medications. The IOP mea-
sured at each visit was then used to calculate the change
from baseline. A Kaplan-Meier analysis was performed
starting at 1month postoperatively and using the follow-
ing criteria for qualified success and complete success:
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Complete success was defined as an IOP reduction of
at least 20% and an IOP value below 18 mmHg without
medication. Qualified success was defined as an IOP re-
duction of at least 20% and an IOP value below 18
mmHg with or without medication. In order to calcu-
late differences between pre- and postoperative values,
the parametric T-test was used. Also, the non-paramet-
ric Wilcoxon sign rank test was used for determining
statistical significance within a group (p < 0.05 consid-
ered statistically significant). For determining statistical
significance between both groups, the non-parametric
Mann-Whitney U test and the t-Test for independent
samples were performed (p < 0.05 considered statisti-
cally significant). In all other cases chi-square tests
were applied (p < 0.05 considered statistically
significant).
Results
Overall, medical records of 110 eyes were included in
this analysis. Of these, 67 eyes with POAG and 43 eyes
with PXG had received a XEN45 gel implant. In the
POAG group, the XEN stent was implanted in combin-
ation with cataract surgery in eight eyes, while 58 eyes
received the XEN stent as standalone procedure. For
one patient of the POAG group the information
whether the XEN stent was implanted standalone or in
combination with cataract surgery was missing. In the
PEX group, nine eyes were treated with combined sur-
gery, while 34 eyes received the XEN stent as standa-
lone procedure. The number of eyes was stable at all
postoperative visits in both groups. Demographic and
baseline characteristics are displayed in Table 1. There
was no statistically significant difference regarding
demographic and baseline characteristics between the
two groups (p > 0.05).
Both groups showed a significant reduction in IOP,
which started on the first day after surgery and contin-
ued for the entire follow-up period of one year. At 12
months postoperatively, the mean IOP had significantly
decreased by 54.0% from preoperatively 31.85 ± 8.5
mmHg to 13.99 ± 2.6 mmHg in the POAG group, (p =
0.000; Wilcoxon test), and by 55.2% from 31.63 ± 9.0
mmHg to 13.28 ± 3.1 mmHg in the PXG group respect-
ively (p = 0.000; Wilcoxon test). No significant differ-
ences between the two groups were detected at any
time during follow-up observation (p > 0.085 at each
postoperative visit; t-Test) (Fig. 1). The proportion of
eyes per group that achieved target pressure values of
18 mmHg, 15 mmHg and 13 mmHg one year postoper-
atively is shown in Fig. 2.
The anti-glaucoma medication was reduced in both
groups in the median from preoperative 3 medications
to 0 medications in the entire postoperative course.
The mean number of anti-glaucoma medications had
Table 1 Demographics and baseline characteristics
POAG
(n = 67)
PEXG
(n = 43)
Age (years),
mean ± SD (range)
69.6 ± 13.7
(34–91)
74.0 ± 8.3
(51–89)
Gender, n (%)
Male 26 (38.8) 20 (46.5)
Female 41 (61.2) 23 (53.5)
Operated Eye, n (%)
OD (right eye) 39 (58.2) 22 (51.2)
OS (left eye) 28 (41.8) 21 (48.8)
Cup to Disc Ratio,
mean ± SD (range)
0.82 ± 0.13
(0.4–1.0)
0.80 ± 0.10
(0.6–1.0)
Lens status, n (%)
Phakic 62 (92.5%) 39 (90.7%)
Pseudophakic 5 (7.5%) 4 (9.3%)
Prior glaucoma
intervention, n (%)
none 22 (32.8%) 14 (32.6%)
Trabeculectomy 13 (19.4%) 6 (14.0%)
Laser 4 (6.0%) 0 (0.0%)
CPC 13 (19.4%) 6 (14.0%)
Microstenta 10 (14.9%) 13 (30.2%)
Phacoemulsification 5 (7.5%) 4 (9.3%)
IOP (mmHg),
mean ± SD (range)
31.85 ± 8.5
(20–65)
31.63 ± 9.0
(20–59)
Number of medication,
mean ± SD (range)
3.25 ± 0.8
(2–5)
3.05 ± 1.0
(0–5)
POAG primary open angle glaucoma, PEXG pseudoexfoliation glaucoma, CPC
Cryophotocoagulation, IOP intraocular pressure, SD standard deviation
aother than XEN gel implant
Fig. 1 Mean IOP at each study visit in PXG eyes (n = 43) und POAG
eyes (n = 67) respectively. Error bars indicate SD for the mean. Within
each group, the mean IOP was significantly reduced from baseline
at any visit during the follow-up period (p = 0.000; Wilcoxon test).
Between groups, no significant differences were observed (p > 0.085
at each visit; t-Test)
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significantly decreased from 3.25 ± 0.8 at baseline to
0.3 ± 0.7 medications at 12 months postoperatively in
POAG eyes (p = 0.000; Wilcoxon test), and from 3.05 ±
1.0 to 0.3 ± 0.6 medications in PXG eyes (p = 0.000;
Wilcoxon test). No significant differences between the
groups were observed at any time during follow-up
(p > 0,4 at each postoperative visit) (Fig. 3). At 12
months postoperatively, 88.1% of POAG eyes and
83.1% of PXG eyes were completely off drops.
One year after XEN45 implantation, 76.1% of eyes
with POAG and 72.1% of those with PXG had achieved
qualified success (IOP reduction of at least 20% and an
IOP value below 18 mmHg with or without medica-
tion). Complete success (IOP reduction of at least 20%
and an IOP value below 18 mmHg without medication)
was experienced by 64.2% of POAG eyes and by 55.8%
of PXG eyes. The results of the Kaplan-Meier analysis
using qualified success criteria and complete success
criteria are shown in Figs. 4 and 5.
Overall, we had 28 cases of failure (i.e. IOP > 18mmHg
and/or IOP reduction < 20%; with or without medication)
after 12months due to reduced filtration by late fibrosis of
the bleb area. Of these, there were 16 failures in the
POAG group and 12 failures in the PXG group.
In the early postoperative phase, between week 1 and
3months, 29.9% eyes in the POAG group required need-
ling to enhance the outflow, while this was the case in
34.9% of PXG eyes respectively. The difference between
both groups was not statistically significant (p = 0.058;
t-Test). Twelve of 110 eyes received a single MMC in-
jection between the first and third month (7 POAG
eyes and 5 PXG eyes). Hypotony (IOP ≤ 6 mmHg) was
observed in 2 POAG eyes (3.0%) and 5 PXG eyes
(11.7%) at 1 month (p = 0.108; Fisher’s exact test).
Fig. 2 Proportion of eyes reaching a certain target pressure at 12 months postoperatively. Comparison of eyes with POAG or PXG
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Neither of the two groups had any cases of wound leak-
age, corneal alterations, device exposure or migration,
choroidal effusion or hemorrhage, choroidal detach-
ment, or endophthalmitis during the follow-up.
Discussion
The purpose of our retrospective data analysis was to
evaluate and compare the efficacy and safety results of
the XEN45 gel implant in patients with PXG and
POAG. Within the last years, various MIGS devices
have been developed with the aim to provide less inva-
sive methods of decreasing IOP in glaucoma patients
than traditional surgery and reducing the patients’ de-
pendency on topical medications [8]. Several clinical
studies have shown that the XEN45 gel implant pro-
vides a significant and enduring reduction of IOP and
anti-glaucoma medication [14–19]. Since these studies
have focused on POAG patients, very little data is
Fig. 4 Kaplan-Meier plots of the cumulative probability of failure using the qualified success criteria. (≥20% IOP reduction and an IOP of less than
18mmHg with or without medication and/or without any secondary intervention). The curve indicates that 76.1 and 72.1% of eyes with POAG
(dotted line) and PXG (solid line) respectively achieved qualified success until 12 months postoperatively. The difference was statistically
not significant (p = 0.626; LogRank)
Fig. 3 Mean number of medication at each study visit in PXG eyes (n = 43) und POAG eyes (n = 67) respectively. Error bars indicate SD for the
mean. Within each group, the mean number of medication was significantly reduced from baseline at any visit during the follow-up
period (p = 0.000; Wilcoxon test). Between groups, no significant differences were observed (p > 0,233 at each visit)
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available on PXG, the most common secondary glau-
coma [22]. However, because of the aggressive course
of the disease and their poor response to medical ther-
apy [23], PXG patients in particular could probably
benefit from an early and less invasive intervention.
Our results show that in both patient groups a strong
and comparable IOP decrease as well as reduction of
anti-glaucoma medication can be achieved with the
XEN45 gel implant. In POAG eyes as well as in PXG
eyes, we observed a significant reduction in the mean
IOP by more than 50% to a mean IOP below 15 mmHg
at each postoperative visit. In both groups, the IOP
lowering effect started on the first postoperative day
and continued throughout the follow-up period. Add-
itionally, in both patient groups the mean number of
anti-glaucoma medications was significantly reduced
after XEN45 implantation and more than 80% of eyes
were completely off drops. This substantial reduction of
anti-glaucoma medication achieved in both patient
groups may contribute to a better quality of life and
can increase patients’ satisfaction with their therapy
[24]. At the same time, the XEN45 had a reliable safety
profile with no severe complications. We did not ob-
serve any significant differences regarding efficacy and
safety between the two groups. However, even if the
differences were not statistically significant, hypotony
of less than 6 mmHg was more frequent in PXG eyes
one month postoperatively. This may be due to the fact
that some pseudoexfoliative material has been removed
by rinsing the anterior chamber during implantation of
the XEN45, thus improving fluid drainage. Neverthe-
less, all cases of hypotony were resolved after six
months and no choroidal effusion was observed.
A total of 17 eyes in our study received the XEN im-
plant in combination with cataract surgery (8 POAG
eyes, 9 PXG eyes). With regard to IOP and number of
medications at baseline and after 12 months we could
not find any statistical differences between the different
subgroups, however, since the number of combined
cases is very low (< 10 in the respective subgroups),
these results should be viewed with the utmost caution
and should not be overinterpreted.
Our results are well in line with data from other clin-
ical studies evaluating the efficacy and safety of the
XEN45 gel implant in patients with POAG [14–19].
Moreover, our results, collected in 43 eyes with PXG, a
very similar to the data from Ilveskoski and Tuuminen
who report clinical results of XEN45 gel implant in 10
patients with PXG. In this group of patients, the mean
IOP was reduced by 47.4% from 33 mmHg preopera-
tively to 10.2 mmHg at six months postoperatively and
mean medication had decreased from 2.4 to 0.9
medications [25].
As the XEN45 gel implant uses the same outflow path
as the surgical gold standard trabeculectomy, our study
results are not comparable to those of other MIGS
Fig. 5 Kaplan-Meier plots of the cumulative probability of failure using the complete success criteria. (≥20% IOP reduction and an IOP of less
than 18 mmHg with or without medication and/or without any secondary intervention). The curve indicates that 64.2 and 55.8% of eyes with
POAG (dotted line) and PXG (solid line) respectively achieved complete success until 12 months postoperatively. The difference was statistically
not significant (p = 0.374; LogRank)
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devices which target the natural outflow pathways of
aqueous humor. Overall, our results indicate a strong
IOP-lowering effect after XEN45 implantation which
can be achieved in POAG patients as well as in PXG
patients and is almost comparable to that of conven-
tional filtrating glaucoma surgery [6], although how-
ever, in the absence of a prospective, randomized trial,
it is difficult to draw any major conclusions versus tra-
beculectomy. At the same time, typical safety risks of
traditional incisional glaucoma surgery, such as
hypotony-related complications, scarring, foreign body
reaction, cataract formation, and surgically induced
astigmatism are almost negligible in this ab-interno
procedure. Therefore, given the marked and enduring
IOP-lowering effect of the XEN45 and its reliable safety
profile, this micro-invasive procedure might be consid-
ered at an earlier stage of glaucoma disease than con-
ventional filtrating glaucoma surgery. Especially in PXG
patients, who often respond only weakly to medical
therapy and exhibit rapid disease progression [23], this
approach may help to achieve a low target IOP with re-
duced medication at an earlier stage. Moreover, this
strategy would preserve the conjunctiva if further glau-
coma filtrating surgery interventions might be required
to control IOP more efficiently.
Our study has limitations that should be addressed.
First, it was a retrospective analysis of single center data,
however, this setting reflects the everyday clinical routine
and thus provides important insights into the efficiency
and safety of the XEN45 gel implant in everyday clinical
practice. Secondly our results are only out to 12months
which is a relatively short time in a lifetime chronic dis-
ease. Thirdly no consistent follow up of perimetry data
was available, as preoperative perimetry assessments had
been performed in the respective private practices, before
the patients were referred to our clinic. Nevertheless, all
patients appeared at our department with clinical signs of
progression or uncontrolled IOP values, respectively.
However, despite its limitations, this study contrib-
utes to increasing evidence showing the safety and effi-
cacy of the XEN45 gel implant. This procedure
provided significant and comparable reduction in IOP
and anti-glaucoma medication during the entire
follow-up period in POAG and PXG eyes, suggesting
that it might be a noteworthy alternative to traditional
filtering procedures in patients with POAG and PXG
respectively. To confirm these one-year results, further
prospective, randomized studies with longer follow-ups
are required to evaluate the efficacy and safety of this
procedure in PXG patients.
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